tbuckley/cabot-search huggingface dataset:
PD1-1-6: Identification of polymorphisms in the survivin gene and their association with lung cancer risk
Authors: Eunjin Kim, Km Kim, Jineun Choi, Jinsung Jang, Sungbeom Han, Seungick Cha, Changho Kim, Taehoon Jung, Jaeyong Park
Journal: Journal of Thoracic Oncology (2007)
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Authors: Philip L.S.M. Gordts, Ryan Nock, Ni-Huiping Son, Bastian Ramms, Irene Lew, Jon C. Gonzales, Bryan E. Thacker, Debapriya Basu, Richard G. Lee, Adam E. Mullick, Mark J. Graham, Ira J. Goldberg, Rosanne M. Crooke, Joseph L. Witztum, Jeffrey D. Esko
Journal: Journal of Clinical Investigation (2016)

Hypertriglyceridemia is an independent risk factor for cardiovascular disease, and plasma triglycerides (TGs) correlate strongly with plasma apolipoprotein C-III (ApoC-III) levels. Antisense oligonucleotides (ASOs) for ApoC-III reduce plasma TGs in primates and mice, but the underlying mechanism of action remains controversial. We determined that a murine-specific ApoC-III-targeting ASO reduces fasting TG levels through a mechanism that is dependent on low-density lipoprotein receptors (LDLRs) and LDLR-related protein 1 (LRP1). ApoC-III ASO treatment lowered plasma TGs in mice lacking lipoprotein lipase (LPL), hepatic heparan sulfate proteoglycan (HSPG) receptors, LDLR, or LRP1 and in animals with combined deletion of the genes encoding HSPG receptors and LDLRs or LRP1. However, the ApoC-III ASO did not lower TG levels in mice lacking both LDLR and LRP1. LDLR and LRP1 were also required for ApoC-III ASO-induced reduction of plasma TGs in mice fed a high-fat diet, in postprandial clearance studies, and when ApoC-III-rich or ApoC-III-depleted lipoproteins were injected into mice. ASO reduction of ApoC-III had no effect on VLDL secretion, heparin-induced TG reduction, or uptake of lipids into heart and skeletal muscle. Our data indicate that ApoC-III inhibits turnover of TG-rich lipoproteins primarily through a hepatic clearance mechanism mediated by the LDLR/LRP1 axis.
Renal Function in Atrial Fibrillation
Authors: Ziad Hijazi, Lars Wallentin
Journal: Circulation (2016)

Articles, see pp 24 and 37 C ardiac function and renal function gradually decrease with aging.Therefore, atrial fibrillation, as an expression of myocardial dysfunction, and conditions with reduced renal filtration of endogenous and exogenous substances often coexist.Both cardiac dysfunction and renal dysfunction are associated with increased risk of thromboembolism, which is further amplified by concurrent atrial fibrillation.Oral anticoagulation for stroke prevention is therefore commonly used in patients with atrial fibrillation and poor or worsening renal function.The clinical dilemma of balancing the risk of ischemic stroke and the risk of major bleeding when deciding on treatment with a non-vitamin K antagonist oral anticoagulant (NOAC) or vitamin K antagonist is thus frequently being encountered in elderly patients with atrial fibrillation.4][5][6][7] Nearly 1 of 5 of the patients enrolled in the atrial fibrillation trials comparing different NOACs with warfarin had a creatinine clearance <50 mL/min. 4,6,7In these trials, the risk of stroke, death, and bleeding was higher among patients with lower renal function at baseline in both the warfarin and NOAC arms.Substudies on outcomes in relation to renal function for the factor Xa inhibitors apixaban and rivaroxaban and the factor IIA inhibitor dabigatran have demonstrated that the superior efficacy and safety of these NOACs seen in the overall trial population extend to patients with renal dysfunction. 4,6,7Apixaban was even associated with a larger benefit in major bleeding compared with warfarin in patients with atrial fibrillation and renal dysfunction. 7The consistent effects of factor Xa inhibitors in patients with renal dysfunction are further supported by the current findings from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48). 1 In the main trial, the factor Xa inhibitor edoxaban at a dose of 60 mg once daily was noninferior to warfarin for the prevention of stroke or systemic embolism and lowered the risk of major bleeding by 20%.The current data demonstrated that these results were sustained in patients with renal dysfunction at entry into the trial (creatinine clearance of 30-50 mL/min). 8][10][11] Thus, for all NOACs, there are recommendations to use a lower dose in patients with poor renal function according to the individual summary of product characteristics.So far, the focus has been on the consequences of renal impairment in relation to cardiovascular risk and the selection of the most suitable antithrombotic treatment.However, little is known about the optimal dose in patients with good renal function, for example, in those with high creatinine clearance (>95 mL/min).This issue was initially highlighted during the US Food and Drug Administration Advisory Committee review on edoxaban with the unexpected finding of higher rates of stroke with edoxaban compared with warfarin in
Prognostic index model for overall survival in advanced unresectable pancreatic cancer from GEST study
Authors: Yasuo Hamamoto, Michitaka Nagase, Shinichi Egawa, Hideki Ueno, Shinichi Ohkawa, Akihiro Funakoshi, Shoji Nakamori, Masashi Kanai, Yasuo Ohashi, Junji Furuse
Journal: Annals of Oncology (2015)
THE CHEMICAL NATURE OF ENZYMES
Authors: J B SUMNER
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia
Authors: Eduard J. Libourel, Clara P. W. Klerk, Yvette van Norden, Moniek P. M. de Maat, Marieke J. Kruip, Pieter Sonneveld, Bob Löwenberg, Frank W. G. Leebeek
Journal: Blood (2016)
Nursery policies on conjunctivitis may encourage GPs to prescribe antibiotics
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Nurseries’ policies excluding children with acute infective conjunctivitis until they recover or have been treated mean that GPs are pressurised by parents to prescribe antibiotics for children who do not need them, research published in the British Journal of General Practice shows.1

Although Public Health England recommends that children with acute infective conjunctivitis do not need to be excluded from childcare, the care providers set their own sickness policies. Researchers from the University of Birmingham conducted an audit of childcare providers’ sickness policies in …
Nitrogen, Sulfhydryl, and Disulfide Contents in Normal and Cancer Sera and in Their Albumin and Globulin Fractions. Action of Sulfite on Disulfide Groups in Normal and Cancer Sera&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: I. M. Kolthoff, W. Stricks, Loes Morren, A. Heyndrickx
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Nitrogen, Sulfhydryl, and Disulfide Contents in Normal and Cancer Sera and in Their Albumin and Globulin Fractions. Action of Sulfite on Disulfide Groups in Normal and Cancer Sera Get access I. M. Kolthoff, I. M. Kolthoff School of Chemistry, University of Minnesota, Minneapolis, Minn. Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Stricks, W. Stricks School of Chemistry, University of Minnesota, Minneapolis, Minn. Search for other works by this author on: Oxford Academic PubMed Google Scholar Loes Morren, Loes Morren School of Chemistry, University of Minnesota, Minneapolis, Minn. Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Heyndrickx A. Heyndrickx School of Chemistry, University of Minnesota, Minneapolis, Minn. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 6, June 1954, Pages 1233–1245, https://doi.org/10.1093/jnci/14.6.1233 Published: 01 June 1954 Article history Received: 15 December 1953 Published: 01 June 1954
Alemtuzumab in Patients with Advanced Mycosis Fungoids: First Interim Report.
Authors: Brady E. Beltrán-Gárate, Julia Huamani-Zavala, Alfredo Aronés-Valdivia, Antonio A. Carrasco-Yalan, Fernando Hurtado de Mendoza, Henry L. Gómez-Moreno
Journal: Blood (2006)
Chemotherapy-induced peripheral neuropathy management.
Authors: Janet Margaret Schloss, Maree Colosimo, Luis Vitetta
Journal: Journal of Clinical Oncology (2016)

154 Background: Neurological complications such as chemotherapy-induced peripheral neuropathy (CIPN) and neuropathic pain are frequent side-effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention and treatment of these neurological complications be implemented to minimize the burden experienced by patients undergoing these treatments. Methods: To determine the potential use of pharmaceuticals, nutraceuticals and herbal medicines as adjuvants in cancer treatments a critical literature review was conducted by electronic and manual search on nine databases. These include PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, Google Scholar and two Chinese databases CNKI and CINAHL. Thirty studies were selected for pharmaceutical agents, twenty-four studies for nutraceuticals and thirty-four studies for herbal medical trials. Seven acupuncture trials were also identified in relation to CIPN management. Data was collated and organised into chemotherapy drugs, agent’s trialled, number of participants, results and recommendations. Results: For pharmaceutical agents, amifostine has possible ototoxicity protection for children in cisplatin and duloxetine as a treatment option for pain. For nutraceuticals, vitamin E was found to have protective abilities for cisplatin ototoxicity, omega 3 fatty acids for taxane administration and vitamin B6 and lipoic acid for oxaliplatin CIPN. In herbal medicine, Goshajinkigan showed great promise for oxaliplatin-IPN protection. Vitamin B12 deficiencies have also been found to increase the onset and severity of CIPN. Conclusions: Currently, no pharmaceutical, nutraceutical or complementary agent has been found to be completely beneficial in preventing or treating CIPN. It is suggested clinicians identify the best option from the research to assist patients in both possible prevention and treatment of CIPN. In addition, research has found that a vitamin B12 deficiency may potentiate moderate to severe CIPN presentation and testing of this vitamin is suggested.
Histological and Histochemical Effects of Cortisone and an Anabolic Androgen on Long Bones of Young Cockerels and Rats
Authors: A E RODIN, K KOWALEWSKI
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neuropsychological functioning in detoxified alcoholics between 18 and 35 years of age
Authors: M J Eckardt, J M Stapleton, R R Rawlings, E Z Davis, D M Grodin
Journal: American Journal of Psychiatry (1995)

The authors determined 1) cognitive functioning in detoxified alcoholics who had alcohol-related problems for a relatively brief time and 2) relationships between neuropsychological test scores and recent and chronic alcohol consumption patterns, childhood symptoms of hyperactivity/minimal brain dysfunction, and extent of familial alcoholism.The subjects were 101 detoxified, drug-free alcoholics between 18 and 35 years of age who had consumed excessive amounts of alcohol (average of 114 g four to five times per week) for an average of 6 years. An average of 39 days after the last drink each alcoholic was given an extensive battery of neuropsychological tests assessing language skills, attention, motor skills, intelligence, memory, and cognitive functioning related to the frontal regions of the brain.Only four individuals evidenced mild cognitive dysfunction. Current psychiatric condition, anxiety and depressive states, and liver dysfunction were not related to cognition. Relationships of cognition of lifetime estimates of alcohol consumption (average of 189 kg) and number of days from last drink to testing were determined to be nonlinear and suggested that greater lifetime consumption predicted worse performance and that longer abstinence predicted better performance. Neither extent of familial alcoholism nor number of childhood signs and symptoms of hyperactivity/minimal brain dysfunction was predictive of cognition except that more antisocial behavior predicted poorer cognitive functioning.Cognition in young alcoholics, averaging 6 years of excessive alcohol consumption, was within normal limits, even though greater lifetime consumption predicted lower test scores and longer abstinence predicted higher scores.
Analysis of (δβ)0 Thalassemia and HPFH Deletions Suggest a Hierarchy of Cis-Acting Elements Regulating Fetal Hemoglobin Gene Expression.
Authors: Heather L Edward, Tasha Morrison, Jacqueline N Milton, Hong-yuan Luo, Lance Davis, Bernard G Forget, Martin H. Steinberg, David H.K. Chui
Journal: Blood (2014)
Diagnosis and Lithium Treatment of Affective Disorder in the Retarded: Five Case Studies
Authors: Timothy M. Rivinus, Jerold S. Harmatz
Journal: American Journal of Psychiatry (1979)

The authors report on five institutionalized retarded patients who had symptoms strongly suggestive of manic-depressive illness and who showed significant symptom reduction in a single-blind placebo-controlled three-year trial of lithium. The number of illness episodes was reduced, and symptoms decreased in all major illness dimensions. These findings indicate that major affective disorder can be both diagnosed and treated in individuals with primary mental retardation.
PD1-1-8: Detection of epidermal growth factor receptor mutations from serum free DNA of non-small lung cancer patients
Authors: Sle Gi Lo Han, Hae-Yun Jung, Young Mi Whang, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Sang Cheul Oh, Jae Hong Seo, Sang-Won Shin, Jun Suk Kim, Yeul Hong Kim
Journal: Journal of Thoracic Oncology (2007)
Sleep Apnea and Cardiovascular Disease
Authors: Virend K. Somers, David P. White, Raouf Amin, William T. Abraham, Fernando Costa, Antonio Culebras, Stephen Daniels, John S. Floras, Carl E. Hunt, Lyle J. Olson, Thomas G. Pickering, Richard Russell, Mary Woo, Terry Young
Journal: Circulation (2008)

S leep-related breathing disorders are highly prevalent in patients with established cardiovascular disease.6][17][18][19] The purpose of this Scientific Statement is to describe the types and prevalence of sleep apnea and its relevance to individuals who either are at risk for or already have established cardiovascular disease.Special emphasis is given to recognizing the patient with cardiovascular disease who has coexisting sleep apnea, to understanding the mechanisms by which sleep apnea may contribute to the progression of the cardiovascular condition, and to identifying strategies for treatment.This document is not intended as a systematic review but rather seeks to highlight concepts and evidence important to understanding the interactions between sleep apnea and cardiovascular disease, with particular attention to more recent advances in patient-oriented research.Implicit in this first American Heart Association/American College of Cardiology Scientific Statement on Sleep Apnea and Cardiovascular Disease is the recognition that, although holding great promise, this general area is in need of a substantially expanded knowledge base.Specific questions include whether sleep apnea is important in initiating the development of cardiac and vascular disease, whether sleep apnea in patients with establishedThe American Heart Association and the American College of Cardiology Foundation make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel.Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control
Authors: Susanne Famulla, Ulrike Hövelmann, Annelie Fischer, Hans-Veit Coester, Lidia Hermanski, Matthias Kaltheuner, Lars Kaltheuner, Lutz Heinemann, Tim Heise, Laurence Hirsch
Journal: Diabetes Care (2016)

OBJECTIVE Lipohypertrophy (LHT) is common in insulin-treated patients but its exact impact on insulin absorption and action is unclear. RESEARCH DESIGN AND METHODS In this crossover study, 13 patients with type 1 diabetes received subcutaneous abdominal injections of 0.15 units/kg insulin lispro into LHT (confirmed by examination and ultrasound) and normal adipose tissue (NAT). On one day, a euglycemic clamp was performed with two injections each into LHT and NAT, and on another day one injection per region was given before a standardized mixed meal (75 g carbohydrates), all in randomized order. RESULTS Compared with NAT, LHT reduced insulin absorption (mean area under the insulin concentration curve [AUCINS0–4h] 131 vs. 165 h * mU/L [LHT vs. NAT]; Cmax 61 vs. 79 mU/L, P &amp;lt; 0.02, respectively) and effect (areas under glucose infusion rate [GIR] curves [AUCGIR0–4h 625 vs. 775 mg/kg, P &amp;lt; 0.05]) but increased intrasubject variability ([coefficient of variation] AUCINS0–4h 52 vs. 11%, Cmax 55 vs. 15%, AUCGIR0–4h 57 vs. 23%, all P &amp;lt; 0.01). Postprandial blood glucose (BG) concentrations were ≥26% higher with LHT (AUCBG0–5h 731 vs. 513 mg * h/dL, BGmax 199 vs. 157 mg/dL, 2-h BG 150 vs. 104 mg/dL, 5-h BG 145 vs. 81 mg/dL, all P &amp;lt; 0.05) and maximum concentrations occurred later. Hypoglycemia (BG ≤50 mg/dL) occurred numerically less frequently with LHT injection (two vs. six patients), whereas profound hyperglycemia (BG ≥300 mg/dL) only occurred with LHT injection (two patients). Tmax-INS did not differ between LHT and NAT in either study. CONCLUSIONS Insulin absorption and action are blunted and considerably more variable with LHT injection, leading to profound deterioration in postprandial glucose control.
Abstract 431: ScaRNAs Regulate Cardiac Differentiation and Development by Fine Tuning the Spliceosome
Authors: Douglas C Bittel, Brenda Rongish, Nataliya Kibiryeva, Michael Filla, Jennifer Marshall, Michael Artman, James E O’Brien, Rajasingh Johnson
Journal: Circulation Research (2015)

Alternative splicing (AS) of mRNA adds diversity to the proteome and precise regulation of AS is essential for proper development. We recently showed that multiple genes critical for heart development are irregularly spliced in the right ventricle of babies with tetralogy of Fallot (TOF). We also observed reduced expression of several noncoding small cajal body associated RNAs (scaRNAs). scaRNAs direct the biochemical modification of spliceosomal RNAs and are essential for the stability and function of the spliceosome. Our results provide compelling evidence for a direct role of scaRNAs in regulating splicing of genes that are critical for heart development. To further explore this novel paradigm of developmental regulation, we analyzed the transcriptome of stem cells as they differentiated to beating cardiomyocytes. We observed significant alternative splicing with respect to timepoint (with Bonferroni correction and fdr of 5%) in 3,165 of 20,301 (15.6%) total genes. Importantly, there were 79 alternatively spliced genes among 213 genes (37.1%) known to be critical for heart development. This is a significant enrichment in the cardiac network genes (p&lt;0.001). Most of the alternative isoforms are known protein coding variants. In addition, we saw changes in expression of several scaRNAs. scaRNA1 is reduced in the right ventricle of children with TOF and we targeted it for knockdown in the quail embryo model system. Preliminary results revealed dramatic alterations in cardiac morphogenesis and embryonic lethality. At higher levels of the antisense oligo, cells appeared to undergo apoptosis, aggregated inappropriately and failed to gastrulate. Lower concentrations resulted in initiation of gastrulation with some cells from the cardiac lineage traversing the embryonic milieu to contribute to the heart and other organs. Interestingly, these cells appeared to lack protrusive phenotypes, and may be passively moved by neighboring groups of non-electroporated motile cells. Taken together, our results suggest scaRNAs are necessary to maintain the fidelity of the spliceosome and thus play an important role in vertebrate heart development. These observations provide additional new insights into regulatory mechanisms underlying cardiac development.